Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

According to Zacks, “Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company’s technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. “

A number of other research analysts also recently issued reports on the company. HC Wainwright restated a “buy” rating on shares of Asterias Biotherapeutics in a research note on Wednesday. ValuEngine cut Asterias Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $9.19.

Shares of Asterias Biotherapeutics (AST) traded up $0.05 during trading on Wednesday, reaching $2.55. The company had a trading volume of 99,800 shares, compared to its average volume of 163,781. Asterias Biotherapeutics has a 1-year low of $2.00 and a 1-year high of $5.70.

ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Downgrades Asterias Biotherapeutics Inc (AST) to Hold” was first published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.